| |
著者: Carlos Blanco, Muhammad S Raza, Franklin R Schneier, Michael R Liebowitz
雑誌名: Int J Neuropsychopharmacol. 2003 Dec;6(4):427-42. doi: 10.1017/S1461145703003791.
Abstract/Text
Social anxiety disorder (SAD) is a highly prevalent and often disabling disorder. This paper reviews the pharmacological treatment of SAD based on published placebo-controlled studies and published meta-analyses. It addresses three specific questions: What is the first-line treatment of SAD? How long should treatment last? What should be the management of treatment-resistant cases? Based on their efficacy for SAD and common comorbid disorders, tolerability, and safety, SSRIs should be considered as the first-line treatment for most patients. Less information is available regarding the optimal length of treatment, although individuals who discontinue treatment after 12-20 wk appear more likely to relapse than those who continue on medication. Even less empirical evidence is available to support strategies for treatment-resistant cases. Clinical experience suggests that SSRI non-responders may benefit from augmentation with benzodiazepines or gabapentin, or from switching to MAOIs, RIMAs, benzodiazepines or gabapentin. Cognitive-behavioural therapy may also be a helpful adjunct or alternative.
PMID 14609440 Int J Neuropsychopharmacol. 2003 Dec;6(4):427-42. doi: 10.1017/S1461145703003791.
|
